About us

Home > About us > Management team

Management team

management_takayamaKiyoshi TAKAYAMA, Ph.D.
FOUNDER AND PRESIDENT.

Kiyoshi Takayama has a Ph.D. in pharmaceutical science from the Graduate School of Pharmaceutical Sciences, University of Tokyo, Japan. He worked for more than 12 years as a research scientist at Taisho Pharmaceutical Co., Ltd, Japan, where he was involved in various drug discovery programs for chronic inflammation and chronic obstructive pulmonary disease (COPD). He also contributed to research on vascular inflammation conducted by Dr. Libby (a current scientific advisor of NBHL) at Brigham and Women’s Hospital, Harvard Medical School, Boston, USA. After leaving Taisho, Takayama founded NBHL in 2006.

Tomoko SHIMIZU, M.Sc.
DIRECTOR, BUSINESS DEVELOPMENT.

Tomoko Shimizu earned an MSc in biological sciences from the Graduate School of Life and Environmental Sciences at the University of Tsukuba, Japan. She worked on drug discovery programs for Japanese pharmaceutical companies for 5 years before joining NBHL as a research scientist in 2007. Shimizu has expertise in mAbs targeting GPCRs and has been involved in NBHL’s internal pipeline programs. She is currently a board member and manages business development activities.

Makoto TANAKA
DIRECTOR, BUSINESS ADMINISTRATION.

Makoto Tanaka joined Tokio Marine & Nichido Fire Insurance Co., Ltd, Japan, after graduating from university. A former president at Seicomart Co. Ltd, Sapporo, Japan. He joined NBHL in 2012 and is currently a board member.

Yuji URUSHIBATA, Ph.D.
EXECUTIVE OFFICER, HEAD OF THE RESEARCH CENTER.

Yuji Urushibata has a Ph.D. in protein chemistry from The United Graduate School of Agricultural Science, Gifu University, Japan. He joined NBHL as a research scientist in 2009, after working on research projects to develop diagnostic tools at Japan’s National Research Institute of Police Science and National Institute of Advanced Industrial Science and Technology. He has expertise in protein-protein interaction (PPI) drug screening and monoclonal antibody protein chemistry. He is currently an executive officer and manages NBHL’s research activities.

Shoko TANAKA
AUDITOR.

Shoko Tanaka joined Tokio Marine & Nichido Fire Insurance Co., Ltd, Japan, after graduating from college. She worked for Professor Keizo Inoue at the Graduate School of Pharmaceutical Sciences, University of Tokyo, Japan. She is a president at Seico Co., Ltd, Sapporo, Japan, and joined NBHL in 2007.